ETFChannel.com
ICPT Description — Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. Co.'s marketed product, Ocaliva® (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to, Co. is developing OCA for multiple indications, including nonalcoholic steatohepatitis.

Company Name: 
Intercept Pharmaceuticals Inc
Website: 
www.interceptpharma.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ICPT: 
33
Total Market Value Held by ETFs: 
$250,092,858
Total Market Capitalization: 
$2,037,000,000
% of Market Cap. Held by ETFs: 
12.28%
 ETF   ICPT Weight   ICPT Amount 
 VTI   0.01%   $43,655,744         
 VB   0.05%   $39,648,964         
 IWM   0.11%   $36,684,684         
 FBT   2.26%   $32,706,618         
 VBK   0.11%   $23,090,145         
 VXF   0.04%   $22,419,690         
 IBB   0.28%   $18,509,377         
 IWO   0.19%   $13,809,307         
 XT   0.30%   $5,968,036         
 VHT   0.04%   $4,281,857         
List of all 33 ETFs holding ICPT »
Quotes delayed 20 minutes

Strong Buy (3.60 out of 4)
70th percentile
(ranked higher than approx. 70% of all stocks covered)

Analysts Forecast:
ICPT Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding ICPT | Intercept Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.